Seletracetam | CAS#357336-74-4 | synaptic vesicle glycoprotein 2A (SV2A) ligand

MedKoo Cat#: 529409 | Name: Seletracetam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Seletracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand potentially for the treatment of epilepsy

Chemical Structure

Seletracetam

CAS#357336-74-4

Theoretical Analysis

MedKoo Cat#: 529409

Name: Seletracetam

CAS#: 357336-74-4

Chemical Formula: C10H14F2N2O2

Exact Mass: 232.1023

Molecular Weight: 232.23

Elemental Analysis: C, 51.72; H, 6.08; F, 16.36; N, 12.06; O, 13.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

UCB-44212; UCB44212; UCB 44212; Seletracetam.

IUPAC/Chemical Name

(S)-2-((S)-4-(2,2-difluorovinyl)-2-oxopyrrolidin-1-yl)butanamide

InChi Key

ANWPENAPCIFDSZ-RQJHMYQMSA-N

InChi Code

InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1

SMILES Code

O=C(N)[C@H](CC)N1C(C[C@@H](/C=C(F)\F)C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 232.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yang X, Meehan AL, Rothman SM, Dubinsky JM. Seletracetam enhances short term depression in vitro. Epilepsy Res. 2015 Nov;117:17-22. doi: 10.1016/j.eplepsyres.2015.08.006. PubMed PMID: 26320080. 2: Matagne A, Margineanu DG, Potschka H, Löscher W, Michel P, Kenda B, Klitgaard H. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol. 2009 Jul 1;614(1-3):30-7. doi: 10.1016/j.ejphar.2009.04.024. PubMed PMID: 19383493. 3: Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N. Seletracetam (UCB 44212). Neurotherapeutics. 2007 Jan;4(1):117-22. Review. PubMed PMID: 17199025. 4: Hamann M, Sander SE, Richter A. Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. Eur J Pharmacol. 2008 Dec 28;601(1-3):99-102. doi: 10.1016/j.ejphar.2008.10.048. PubMed PMID: 19014930. 5: Pollard JR. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008 Jan;9(1):101-7. Review. PubMed PMID: 18183537. 6: Martella G, Bonsi P, Sciamanna G, Platania P, Madeo G, Tassone A, Cuomo D, Pisani A. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009 Apr;50(4):702-10. doi: 10.1111/j.1528-1167.2008.01915.x. PubMed PMID: 19055493. 7: Correa-Basurto J, Cuevas-Hernández RI, Phillips-Farfán BV, Martínez-Archundia M, Romo-Mancillas A, Ramírez-Salinas GL, Pérez-González ÓA, Trujillo-Ferrara J, Mendoza-Torreblanca JG. Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. Front Cell Neurosci. 2015 Apr 10;9:125. doi: 10.3389/fncel.2015.00125. PubMed PMID: 25914622; PubMed Central PMCID: PMC4392693. 8: Kuntz T, Schubert MA, Kleinebudde P. Increased compactibility of acetames after roll compaction. Eur J Pharm Biopharm. 2011 Jan;77(1):164-9. doi: 10.1016/j.ejpb.2010.09.013. PubMed PMID: 20932904. 9: Frycia A, Starck JP, Jadot S, Lallemand B, Leclercq K, Lo Brutto P, Matagne A, Verbois V, Mercier J, Kenda B. Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression. ChemMedChem. 2010 Feb 1;5(2):200-5. doi: 10.1002/cmdc.200900436. PubMed PMID: 20039359. 10: Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol Scand Suppl. 2005;181:68-72. PubMed PMID: 16238713. 11: Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010 Feb 12;70(3):287-312. doi: 10.2165/11319230-000000000-00000. Review. PubMed PMID: 20166767. 12: Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. Review. PubMed PMID: 19443931. 13: Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem. 2008 Feb 14;2:21-39. PubMed PMID: 19787095; PubMed Central PMCID: PMC2746576. 14: Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. Review. PubMed PMID: 16732716. 15: Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006 Jun;69(3):273-94. Review. PubMed PMID: 16621450; PubMed Central PMCID: PMC1562526. 16: Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease: an update. Curr Opin Investig Drugs. 2006 Jan;7(1):25-32. Review. PubMed PMID: 16425668. 17: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007 Jan;73(1):1-52. PubMed PMID: 17158031.